Alvotech files EU application for Eylea HD biosimilar AVT29
Alvotech filed a European Medicines Agency application for AVT29, a proposed biosimilar to Eylea 8 mg (Eylea HD). Submission was made as a line extension to the existing European marketing authorization for Mynzepli, its Eylea 2 mg biosimilar. Partner Advanz Pharma will handle registration, commercialization in Europe